Epidemiology of human T-lymphotropic virus type III and the risk of the acquired immunodeficiency syndrome

Ann Intern Med. 1985 Nov;103(5):665-70. doi: 10.7326/0003-4819-103-5-665.

Abstract

The discovery of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) has opened a window to the understanding of the spectrum of the acquired immunodeficiency syndrome (AIDS) and related clinical syndromes. Analysis of risk factors for seropositivity has shown that HTLV-III is transmitted most efficiently via routes that involve close personal contact or parenteral exposure. Longitudinal studies have shown that HTLV-III infection has a long latent period. The prevalence of AIDS in different geographic areas and among different risk groups appears to depend in part on duration of exposure. Co-factors for AIDS outcome such as manner and route of exposure, underlying immune status, and host susceptibility are also likely to play a role in risk.

Publication types

  • Review

MeSH terms

  • Acquired Immunodeficiency Syndrome / epidemiology*
  • Acquired Immunodeficiency Syndrome / transmission
  • Antibodies, Viral / analysis*
  • Deltaretrovirus / immunology*
  • Electrophoresis
  • Enzyme-Linked Immunosorbent Assay
  • False Positive Reactions
  • Haiti / ethnology
  • Hemophilia A / therapy
  • Homosexuality
  • Humans
  • Injections, Intravenous
  • Lymphatic Diseases / microbiology
  • Male
  • Risk
  • Sexual Behavior
  • Substance-Related Disorders / complications
  • Time Factors

Substances

  • Antibodies, Viral